CRIS Current Research Information System

To determine the maximum tolerated dose (MTD) of a short-course accelerated radiotherapy and its feasibility for symptomatic palliation of advanced head and neck cancer or head and neck metastases from any primary site.

Farina E, C.J. (2018). Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer. ANTICANCER RESEARCH, 38(4), 2409-2414 [10.21873/anticanres.12491].

Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer

Cammelli S;Farioli A;Buwenge M;Morganti AG
2018

Abstract

To determine the maximum tolerated dose (MTD) of a short-course accelerated radiotherapy and its feasibility for symptomatic palliation of advanced head and neck cancer or head and neck metastases from any primary site.
2018
Farina E, C.J. (2018). Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer. ANTICANCER RESEARCH, 38(4), 2409-2414 [10.21873/anticanres.12491].
Farina E, Capuccini J, Macchia G, Caravatta L, Nguyen NP, Cammelli S, Farioli A, Zanirato Rambaldi G, Cilla S, Wondemagegnhu T, Uddin AFMK, Sumon MA, ...espandi
1.01 Articolo in rivista
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/645359
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 13
social impact